InMed Pharmaceuticals (NASDAQ:INM – Get Free Report) and Silo Pharma (NASDAQ:SILO – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability and analyst recommendations.
Risk & Volatility
InMed Pharmaceuticals has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500. Comparatively, Silo Pharma has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500.
Profitability
This table compares InMed Pharmaceuticals and Silo Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| InMed Pharmaceuticals | -132.87% | -80.85% | -68.11% |
| Silo Pharma | -6,726.39% | -81.75% | -66.35% |
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| InMed Pharmaceuticals | $4.94 million | 0.92 | -$8.16 million | ($2.89) | -0.48 |
| Silo Pharma | $70,000.00 | 53.13 | -$4.23 million | ($4.36) | -0.54 |
Silo Pharma has lower revenue, but higher earnings than InMed Pharmaceuticals. Silo Pharma is trading at a lower price-to-earnings ratio than InMed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of current ratings for InMed Pharmaceuticals and Silo Pharma, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| InMed Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
| Silo Pharma | 1 | 0 | 0 | 0 | 1.00 |
Insider & Institutional Ownership
20.1% of InMed Pharmaceuticals shares are owned by institutional investors. Comparatively, 5.6% of Silo Pharma shares are owned by institutional investors. 0.9% of InMed Pharmaceuticals shares are owned by company insiders. Comparatively, 3.6% of Silo Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
InMed Pharmaceuticals beats Silo Pharma on 7 of the 11 factors compared between the two stocks.
About InMed Pharmaceuticals
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company’s lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
About Silo Pharma
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company’s two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company’s research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
Receive News & Ratings for InMed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
